Home
overview
Once again, the 6th Annual Diabetes Conference brings together all the leading players in diabetes drug development.

Our top speakers will help you to evaluate the limitations of existing diabetes therapies. They will assist you in identifying where new advances are being made, and which approaches are best for you and your pipeline.

This Conference agenda is packed with actionable data that you can take away to enhance your own diabetes portfolio.

Speakers include: Novo Nordisk, Roche, Aventis, Pfizer, Lilly, Probiodrug, TNO Pharma, Arena Pharma, J&J, Abbott, Genzyme, Glaxo, Institute for Metabolic Research, ISIS, Ingenium and VTT.

This year's agenda includes two invaluable contributions from Pfizer by:

  • Dr Michael Jirousek, Director & Head, Diabetes, Obesity Therapeutic Area, Pfizer
  • Dr Andrew Swick, Director, Cardiovascular & Metabolic Diseases, Pfizer
Plus, new diabetes sessions led by...
  • Dr Eric Lewis, Global Director, World Wide Development, GlaxoSmithKline
  • Dr Monique Berwaer, Head, Metabolic Disease, Johnson & Johnson
  • Prof Manfred Ganz, Head, Medical Assessment, Roche Diagnostics
  • Dr Michael Trautmann, Medical Fellow, Eli Lilly & Company
  • Dr Cristina Rondinone, Group Leader, Metabolic Diseases Research, Abbott Laboratories
  • Dr Monica Einstein, Research Fellow, Merck
  • Dr Cynthia Arbeeny, Vice President, Metabolic Diseases, Genzyme

"A deeper understanding of the basic genetic and molecular mechanisms involved in type 2 diabetes has led to development pipelines bursting with exciting new therapies."

This Conference will bring together market leaders, specialists and renowned academics to talk about the latest innovations in:
  • Diabetes treatment and future therapies
  • Overcoming the limitations of current therapies
  • The intersection of obesity, macronutrient regulation and type II
  • How to idenfiy potential of GLP-1 compounds
  • How to improve metabolic control
  • DPPIV inhibitors
  • AMP kinases
  • 11 betaHSD enzyme inhibitors
  • Animal models
  • Identifying the most promising new pathways from lab investigations
  • Using antisense technology to discover new diabetes drugs
  • Novel diabetes related gene discovery
  • Systems biology tools for diabetes research
  • Insulin delivery without injection
  • RNAi-based gene silencing
  • New approaches to disease progression
  • Future targets for pharmacological intervention
  • Competitive and pricing challenges in the marketplace

Programme highlights include:
  • GLP-1 AND INCRETIN MIMETICS: Hear about Extenatide and pre-clinical and clinical experiences with it
  • DPP lV INHIBITION AND SAFETY: Improving metabolic control and the long term effects of DPP IV inhibition on different parameters of type ll diabetes
  • NOVEL APPROACHES AND ALTERNATIVE METHODS OF ADMINISTRATION: Learn about promising new pathways being investigated in the lab
  • DEVELOPING ANTISENSE INHIBITORS FOR METABOLIC DISEASES: Assess how technology is being applied to treat metabolic disorders
  • INDUSTRY EXPERTS: Network with leaders in the field and gain an insight into their experiences

Who will you meet at this event? Previous attendees include:
Bio-Kinetic, PPL Therapeutics, Abbott Labs, Merck, Genzyme, Novo Nordisk, Amylin, AstraZeneca, Takeda, Ligand, Amylin, Roche, Forest Labs, Eli Lilly, Millennium, Novartis, J&J, Bristol Myers Squibb, Calyx, Aventis, Boehringer Ingelheim, Amersham Biosciences, Pfizer, IMS Health, Genzyme, Eisai, Ribonomics, Chugai, GlaxoSmithKline, Isis, Aventis, and many, many more...

Conference programme

8:30 Registration and Coffee

9:00 Chairman's Opening Remarks

Dr Richard Carr

Dr Richard Carr, Scientific Vice President, Novo Nordisk

9:10 DIABETES: THE SITUATION AT PRESENT

Prof Manfred Ganz

Prof Manfred Ganz, Head, Medical Assessment, Roche Diagnostics

  • A growing health problem
  • Reasons behind growth
  • What/who is responsible?
  • Economic implications
  • Rising to the challenge of educating the public
  • Future therapies – advanced and effective treatments
  • Lack of awareness and the need to raise
  • Preventative strategies
  • 9:50 LIMITATIONS OF EXISTING THERAPIES

    Prof Juergen Sandow

    Prof Juergen Sandow, Senior Research Scientist, Aventis

  • Current therapies – injected and oral insulin
  • Where are they going wrong?
  • Gaps that need to be filled
  • What more can be done
  • Challenges to overcome
  • 10:30 Morning Coffee

    11:00 DPP IV INHIBITION AND SAFETY

    Dr Hans-Ulrich Demuth

    Dr Hans-Ulrich Demuth, Chief Executive Officer, Chief Scientific Officer, Probiodrug

  • How to achieve inhibition
  • Establishing mechanisms underlying beneficial effects
  • Long term effects of DPP IV inhibition on different parameters of type 2 diabetes
  • Research – are outcome results specific enough?
  • Side effects and safety issues
  • 11:40 GLP-1 AND INCRETIN MIMETICS

    Dr Michael Trautmann

    Dr Michael Trautmann, Medical Fellow, Eli Lilly & Company

  • GLP-1 physiology
  • Multiple antidiabetic actions
  • Overview of Extenatide
  • Mechanism of action
  • Pre-clinical and clinical experience with Extenatide
  • 12:20 Networking Lunch

    13:50 LIRAGLUTIDE

    Lotte Bjerre Knudsen

    Lotte Bjerre Knudsen, , Novo Nordisk

  • Potential of GLP-1 compounds in the treatment of type ll diabetes
  • The rational design and discovery of liraglutide
  • Clinical safety and efficacy of liraglutide in type ll diabetes
  • Restoration of beta-cell function in man
  • Effects on beta-cell mass in animal models of type ll diabetes
  • 14:30 HEPATIC STEATOSIS

    Dr Peter Voshol

    Dr Peter Voshol , Scientist, TNO Pharma

  • Intra- and extrahepatic causes of hepatic steatosis
  • Hepatic steatosis not only secondary, but also primary involved in development of the metabolic syndrome
  • Alterations in hepatic and peripheral VLDL and triglyceride metabolism as a determinant of the metabolic syndrome, and vice versa
  • Lessons from animal models
  • 15:10 Afternoon Tea

    15:40 ORAL INSULIN: MORE THAN SIMPLY ELIMINATING INJECTION

    Dr Michael Goldberg

    Dr Michael Goldberg, Chief Executive Officer, Emisphere Technologies

  • Oral insulin - replaces first phase insulin response
  • Oral Insulin - targets the liver
  • Oral Insulin - clinical data following two weeks of Dosing
  • 16:20 RESTORING FIRST-PHASE INSULIN DYNAMICS IN DIABETES PATIENTS – THE UNANTICIPATED BENEFIT

    Dr Wendell Cheatham

    Dr Wendell Cheatham, Vice President & Medical Director, Mannkind Corporation

  • Discussion of the dynamics of glucose homeostasis in the non-diabetic state
  • First-phase insulin release in diabetes
  • Replacement of the dynamic of first phase insulin release
  • Technosphere /Insulin System - obtained results from studies
  • The window of opportunity
  • 17:00 Chairman’s Closing Remarks and Close of Day One

    8:30 Re-registration and Coffee

    9:00 Chairman's Opening Remarks

    Dr Dominic Behan

    Dr Dominic Behan, Vice President, Research, Arena Pharmaceuticals Inc

    9:10 PROMISING NEW PATHWAYS BEING INVESTIGATED IN THE LAB

    Dr Monique Berwaer

    Dr Monique Berwaer, Head, Metabolic Disease, Johnson & Johnson

  • New drug targets under investigation: overview
  • The potential of 11 bHSD inhibition in the treatment of the metabolic syndrome: dream or reality?
  • 9:50 DISCOVERY OF NEW DRUG TARGETS USING RNAi-BASED GENE SILENCING

    Dr Cristina Rondinone

    Dr Cristina Rondinone, Group Leader & Associate Research Fellow, Metabolic Diseases Research, Abbott Laboratories

  • RNAi: how it works
  • Validation of the technology
  • Is it a useful tool?
  • Validation of targets using RNAi
  • Screening and identification of new targets in liver
  • 10:30 Morning Coffee

    11:00 DIABETES AND THE METABOLIC SYNDROME

    Dr Cynthia Arbeeny

    Dr Cynthia Arbeeny, Vice President, Metabolic Diseases, Genzyme

  • Overview of diabetes as a consequence of derangements in lipid and carbohydrate metabolism
  • How does inflammation, dyslipidemia, hypertension and vascular dysfunction contribute to disease progression?
  • What are the limitations to current therapies?
  • What are the future targets for pharmacological intervention?
  • Will polypharmacy be necessary?
  • 11:40 ALTERNATIVE ROUTES OF INSULIN ADMINISTRATION

    Prof Lutz Heinemann

    Prof Lutz Heinemann, Chief Executive Officer, Business Development, Profil Institute for Metabolic Research

  • Eliminating the injection
  • Other routes of insulin administration
  • Benefits of alternative methods
  • Experimental and clinical results
  • Convenience and compliance
  • Challenges faced in the marketplace – competition and pricing
    Outlook for the future
  • 12:20 Networking Lunch

    13:50 DEVELOPING ANTISENSE INHIBITORS FOR METABOLIC DISEASES

    Dr Sanjay Bhanot

    Dr Sanjay Bhanot, Executive Director, Antisense Drug Discovery , Isis Pharmaceuticals

  • What is antisense technology?
  • Why is it a rational and efficient drug discovery platform?
  • What advantages does it have over traditional drug discovery approaches?
  • How is the technology being applied to treat metabolic disorders?
  • What are the challenges ahead?
  • A look into the future
  • 14:30 A NEW OPPORTUNITY FOR DIABETES TREATMENT

    Dr Klaus Dembowsky

    Dr Klaus Dembowsky, Vice President, Drug Discovery, Ingenium Pharmaceuticals

  • Overview of novel, diabetes-related gene discovery
  • Analysis of gene and result of specific recessive mutations
  • Mouse model provides multiple phenotypic aspects for diabetes
  • Discussion of interplay between insulin and leptin sensitivity
  • Overview of therapeutic hypotheses under investigation
  • 15:10 Afternoon Tea

    15:40 SYSTEMS BIOLOGY & INFORMATICS

    Prof Hans Söderlund

    Prof Hans Söderlund, Director, R&D, VTT Biotechnology

  • Knowledge management solutions based on semantic web technologies for drug discovery, biomedicine and nutrition research
  • Integrating in-house generated data with existing knowledge
  • Biochip technologies for high content screening
  • Metabolomics platform for phenotype characterisation
  • Case study: characterising new PPARg related mouse model
  • 17:00 Chairman’s Closing Remarks and Close of Conference

    +

    Workshops

    Type 2 Diabetes and Beyond: The Untapped Commercial Potential
    Workshop

    Type 2 Diabetes and Beyond: The Untapped Commercial Potential

    Regus-No.1 Poultry
    20th October 2004
    London, United Kingdom

    The Hatton, at etc. venues

    51/53 Hatton Garden
    London EC1N 8HN
    United Kingdom

    The Hatton, at etc. venues

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.